Lantheus vs Neogen
LNTH and NEOG side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LNTH and NEOG compare
Lantheus is the larger company, worth 2.8 times as much as Neogen ($6.6B against $2.4B).
Lantheus grew revenue faster over the last twelve months (2.3% versus −0.33% for Neogen).
Lantheus keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with −6.3% at Neogen.
Lantheus scores higher on the StockData Score (11 against 7 for Neogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LNTH | NEOG |
|---|---|---|
| Size and price | ||
| Market cap | $6.6B | $2.4B |
| Share price | $101.72 | $10.88 |
| Change, 1 year | 91.5% | 70.8% |
| Change, 5 years | 265% | −73.6% |
| Beta (5Y) | 0.41 | 0.86 |
| Employees | 1,193 | 2,636 |
| StockData Score | ||
| Total score | 11 (better) | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 5 (better) | 3 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 24.6× | – |
| P/S | 4.3× | 2.7× (better) |
| P/B | 5.1× | 1.1× (better) |
| EV/EBITDA | 16.9× (better) | 34.5× |
| P/FCF | – | 47.7× |
| PEG | 0.24 | – |
| FCF yield | – | 2.1% |
| Fair value | $91.21 | $7.30 |
| Margin of safety | −11.5% (better) | −49.0% |
| Growth | ||
| Revenue growth (TTM) | 2.3% (better) | −0.33% |
| Revenue growth, 5Y average | 35.3% (better) | 13.2% |
| Net income growth (TTM) | 1.6% | – |
| EPS growth (TTM) | 9.5% | – |
| Profitability | ||
| Gross margin | 60.1% (better) | 47.4% |
| Operating margin | 19.4% (better) | −0.83% |
| Net margin | 17.7% (better) | −6.3% |
| FCF margin | – | 5.6% |
| Return on equity | 22.2% (better) | −2.7% |
| Return on invested capital | 19.7% (better) | −0.17% |
| Financial health | ||
| Debt / equity | 0.44 (better) | 0.74 |
| Net debt / EBITDA | −0.06 | 12.69 (better) |
| Interest coverage | 15.3× | – |
| Current ratio | 3.06 | 3.90 (better) |
| Altman Z-score | 5.52 (better) | 1.35 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 117% | 109% |
| Held by insiders | 2.3% | 0.60% |
| Insider net buying, 12 months | – | −$102K |
| Short interest, % of float | 5.7% | 5.9% |
Go deeper
- LNTH stock overview
- LNTH income statement
- LNTH valuation and score
- NEOG stock overview
- NEOG income statement
- NEOG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.